To be noted, the SGLT2 inhibitors work independently, albeit without insulin, ameliorate blood glucose control in all stages of T2DM in the absence of clinically relevant hypoglycemia, and could be combined with other antidiabetic drugs. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.